Design and evaluation of folate-appended methyl-β-cyclodextrin as a new antitumor agent

  • Risako Onodera
  • Keiichi Motoyama
  • Hidetoshi Arima
Original article
First Online:
Received:
Accepted:

Abstract

Methyl-β-cyclodextrin (M-β-CyD) is widely used as a raft disrupting agent through extraction of cholesterol from lipid rafts which are highly expressed in cell membranes of tumor cells, but it does not have tumor cell-selective action. Meanwhile, the widespread use of folic acid (FA) as a tumor-targeting ligand has been known, because folate receptor (FR) overexpresses in various kinds of epithelial tumor cells. In the present study, in order to obtain more tumor cell-selectivity and antitumor activity of M-β-CyD, we designed folate-appended M-β-CyD (FA-M-β-CyD), and evaluated its physicochemical properties and antitumor activity. The 1H-NMR study demonstrated that FA-M-β-CyD having average degree of substitution of FA (DSF) of 1.0 was prepared. In addition, FA-M-β-CyD (DSF 1.0) was found to be amorphous in a solid state and surface-active. Importantly, FA-M-β-CyD (DSF 1.0) had potent cytotoxicity, compared to M-β-CyD in KB cells, but not in A549 cells. These results suggest that FA-M-β-CyD (DSF 1.0) has the potential as a novel antitumor agent.

Keywords

Folic acid Methyl-β-cyclodextrin Tumor targeting Antitumor drug 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was partially supported by a Grant-in-Aid from Young Scientists (B) from the Ministry of Education, Science and Culture of Japan (22790040).

References

  1. 1.
    O’Brien, M.E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D.G., Tomczak, P., Ackland, S.P., Orlandi, F., Mellars, L., Alland, L., Tendler, C.: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15, 440–449 (2004)CrossRefGoogle Scholar
  2. 2.
    Harata, M., Soda, Y., Tani, K., Ooi, J., Takizawa, T., Chen, M., Bai, Y., Izawa, K., Kobayashi, S., Tomonari, A., Nagamura, F., Takahashi, S., Uchimaru, K., Iseki, T., Tsuji, T., Takahashi, T.A., Sugita, K., Nakazawa, S., Tojo, A., Maruyama, K., Asano, S.: CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 104, 1442–1449 (2004)CrossRefGoogle Scholar
  3. 3.
    Roche, A.C., Fajac, I., Grosse, S., Frison, N., Rondanino, C., Mayer, R., Monsigny, M.: Glycofection: facilitated gene transfer by cationic glycopolymers. Cell. Mol. Life Sci. 60, 288–297 (2003)CrossRefGoogle Scholar
  4. 4.
    Chen, H., Ahn, R., Van den Bossche, J., Thompson, D.H., O’Halloran, T.V.: Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol. Cancer. Ther. 8, 1955–1963 (2009)CrossRefGoogle Scholar
  5. 5.
    Lu, Y., Low, P.S.: Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug. Deliv. Rev. 54, 675–693 (2002)CrossRefGoogle Scholar
  6. 6.
    Hatakeyama, H., Akita, H., Maruyama, K., Suhara, T., Harashima, H.: Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int. J. Pharm. 281, 25–33 (2004)CrossRefGoogle Scholar
  7. 7.
    Miyajima, Y., Nakamura, H., Kuwata, Y., Lee, J.D., Masunaga, S., Ono, K., Maruyama, K.: Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy. Bioconjug. Chem. 17, 1314–1320 (2006)CrossRefGoogle Scholar
  8. 8.
    Kim, I.Y., Kang, Y.S., Lee, D.S., Park, H.J., Choi, E.K., Oh, Y.K., Son, H.J., Kim, J.S.: Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control. Release 140, 55–60 (2009)CrossRefGoogle Scholar
  9. 9.
    Schiffelers, R.M., Koning, G.A., ten Hagen, T.L., Fens, M.H., Schraa, A.J., Janssen, A.P., Kok, R.J., Molema, G., Storm, G.: Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 91, 115–122 (2003)CrossRefGoogle Scholar
  10. 10.
    Leamon, C.P., Low, P.S.: Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today 6, 44–51 (2001)Google Scholar
  11. 11.
    Parker, N., Turk, M.J., Westrick, E., Lewis, J.D., Low, P.S., Leamon, C.P.: Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284–293 (2005)CrossRefGoogle Scholar
  12. 12.
    Szente, L., Szejtli, J.: Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development. Adv. Drug Deliv. Rev. 36, 17–28 (1999)CrossRefGoogle Scholar
  13. 13.
    Uekama, K., Otagiri, M.: Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carrier Syst. 3, 1–40 (1987)Google Scholar
  14. 14.
    Motoyama, K., Arima, H., Toyodome, H., Irie, T., Hirayama, F., Uekama, K.: Effect of 2, 6-di-O-methyl-α-cyclodextrin on hemolysis and morphological change in rabbit’s red blood cells. Eur. J. Pharm. Sci. 29, 111–119 (2006)CrossRefGoogle Scholar
  15. 15.
    Motoyama, K., Toyodome, H., Onodera, R., Irie, T., Hirayama, F., Uekama, K., Arima, H.: Involvement of lipid rafts of rabbit red blood cells in morphological changes induced by methylated β-cyclodextrins. Biol. Pharm. Bull. 32, 700–705 (2009)CrossRefGoogle Scholar
  16. 16.
    Ohtani, Y., Irie, T., Uekama, K., Fukunaga, K., Pitha, J.: Differential effects of α-, β- and γ-cyclodextrins on human erythrocytes. Eur. J. Biochem. 186, 17–22 (1989)CrossRefGoogle Scholar
  17. 17.
    Galbiati, F., Razani, B., Lisanti, M.P.: Emerging themes in lipid rafts and caveolae. Cell 106, 403–411 (2001)CrossRefGoogle Scholar
  18. 18.
    Simons, K., Ehehalt, R.: Cholesterol, lipid rafts, and disease. J. Clin. Invest. 110, 597–603 (2002)Google Scholar
  19. 19.
    Anderson, R.G., Jacobson, K.: A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 296, 1821–1825 (2002)CrossRefGoogle Scholar
  20. 20.
    Motoyama, K., Kameyama, K., Onodera, R., Araki, N., Hirayama, F., Uekama, K., Arima, H.: Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2, 6-di-O-methyl-β-cyclodextrin, not 2, 6-di-O-methyl-α-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells. Eur. J. Pharm. Sci. 38, 249–261 (2009)CrossRefGoogle Scholar
  21. 21.
    Grosse, P.Y., Bressolle, F., Pinguet, F.: Antiproliferative effect of methyl-β-cyclodextrin in vitro and in human tumour xenografted athymic nude mice. Br. J. Cancer 78, 1165–1169 (1998)CrossRefGoogle Scholar
  22. 22.
    Arima, H., Chihara, Y., Arizono, M., Yamashita, S., Wada, K., Hirayama, F., Uekama, K.: Enhancement of gene transfer activity mediated by mannosylated dendrimer/α-cyclodextrin conjugate (generation 3, G3). J. Control. Release 116, 64–74 (2006)CrossRefGoogle Scholar
  23. 23.
    Wada, K., Arima, H., Tsutsumi, T., Chihara, Y., Hattori, K., Hirayama, F., Uekama, K.: Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates. J. Control. Release 104, 397–413 (2005)CrossRefGoogle Scholar
  24. 24.
    Hamasaki, K., Kogure, K., Ohwada, K.: A biological method for the quantitative measurement of tetrodotoxin (TTX): tissue culture bioassay in combination with a water-soluble tetrazolium salt. Toxicon. 34, 490–495 (1996)CrossRefGoogle Scholar
  25. 25.
    Ono, N., Arima, H., Hirayama, F., Uekama, K.: A moderate interaction of maltosyl-α-cyclodextrin with Caco-2 cells in comparison with the parent cyclodextrin. Biol. Pharm. Bull. 24, 395–402 (2001)CrossRefGoogle Scholar
  26. 26.
    Takahashi, K., Hattori, K., Toda, F.: Monotosylated α- and β-cyclodextrins prepared in an alkaline aqueous solution. Tetrahedron Lett. 25, 3331–3334 (1984)CrossRefGoogle Scholar
  27. 27.
    Murakami, T., Harata, K., Morimoto, S.: Synthesis and chiral recognition property of 3-acetylamino-3-deoxy-β-cyclodextrin. Chem. Lett. 17, 553–556 (1988)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Risako Onodera
    • 1
  • Keiichi Motoyama
    • 1
  • Hidetoshi Arima
    • 1
  1. 1.Graduate School of Pharmaceutical SciencesKumamoto UniversityKumamotoJapan

Personalised recommendations